Abbott (NYSE:ABT) today announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD). Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott’s HeartMate 3™ heart pumps to their patients.
Abbott Says Has Capacity And Supply To Support Demand For MCS Devices
Abbott (NYSE:ABT) today announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure
Related Posts
Hey, George Jetson! Flying Taxis Are Coming Soon In Time For Your Birthday
A California startup making flying taxis received a $10 million deposit from United Airlines Holdings Inc (NASDAQ: UAL) with the intention of transporting passengers to and from the airport by air.
Red White & Bloom Closes On PharmaCo Acquisition
Red White & Bloom Brands Inc. (CSE: RWB) (OTC: RWBYF) a multi-state cannabis operator, announced it has received all regulatory approvals and has closed its acquisition of PharmaCo, Inc. via RWB Michigan, LLC, the Company’s wholly-owned subsidiary, in an all-stock t
